1. Executive Session 6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:40
   - Updates
   - DUR Board Schedule for 2014

4. Medical Director Update 6:40 - 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 – 6:50
   - Buprenorphine and Opiates

6. RetroDUR/DUR 6:50 – 7:30
   - Opiate Analgesics: Review of Clinical Guidelines and Summary of Edits/Approaches from other State Medicaid Programs

   (Public comment prior to Board action)

   Abbreviated New Drug Reviews
   - Desvenlafaxine® 24 hr Oral Tablet
   - ForfiVo® XL (bupropion) Extended Release Oral Tablet
   - Lyrica® (pregabalin) Oral Solution
   - Prolensa® (bromfenac 0.07 %) Ophthalmic Solution
   - Simbrinza® (brinzolamide 1 %/ brimonidine 0.2 %) Ophthalmic Suspension
   - Zenzedi® (dextroamphetamine) Oral Tablet

   Full New Drug Reviews
   - Lipruzet® (ezetimibe/atorvastatin) Oral Tablet
   (Public comment prior to Board action)
   ▪ New Cholesterol Treatment Guidelines Released

9. Therapeutic Drug Classes – Periodic Review 7:55 – 8:15
   (Public comment prior to Board action)
   Class review documents available on DVHA web site 12/10/2013 @ Noon
   ▪ Acne Medications: Topical
   ▪ Anti-hypertensives: Angiotensin Converting Enzyme (ACE) Inhibitors and Combinations
   ▪ Anti-hypertensives: Angiotensin Receptor Blockers and Combinations
   ▪ Gastrointestinal: H2 Receptor Antagonists
   ▪ Otic: Anti-Infectives
   ▪ Renal: Phosphate Binders

10. New Managed Therapeutic Drug Classes 8:15 – 8:15
    (Public comment prior to Board action)
    ▪ None

11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:15 – 8:25
    (Public comment prior to Board action)
    ▪ Anti-infectives: Antivirals: Influenza Vaccines
    ▪ Ilaris® (canakinumab) Injection in SIJA (new FDA approved diagnosis)
    ▪ Makena® (hydroxyprogesterone) Injection

12. General Announcements 8:25 – 8:30
    Selected FDA Safety Alerts
    ▪ Acetaminophen: Drug Safety Communication - Association with Risk of Serious Skin Reactions
    ▪ Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
    ▪ Rosiglitazone – FDA lifts prescribing restrictions
    ▪ Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection

13. Adjourn 8:30